This innovative monoclonal protein, Pritoxaximab – formerly known as DXX00601 – shows considerable opportunity in the therapy of acute immune reaction (TRALI). Developed by the company, Pritoxaximab functions by https://www.targetmol.com/compound/pritoxaximab